Navigation Links
Prasco® Announces Authorized Generic Agreement with Shionogi Inc.
Date:7/25/2011

CINCINNATI, July 25, 2011 /PRNewswire/ -- Prasco Laboratories, the Authorized Generics company, announced today it has signed a supply agreement with Shionogi Inc. Under the terms of the agreement, Prasco will market and distribute Mefenamic Acid Capsules, USP 250 mg, the Authorized Generic version of Ponstel®. Prasco intends to begin shipping product immediately in the U.S. under the Prasco label.

"With the introduction of the authorized generic of Shionogi's PONSTEL®, Prasco continues to be the preferred partner for established brand companies to transcend their brands with our Authorized Generics," said Prasco Chief Executive Officer E. Thomas Arington. "We are pleased to have established this relationship with Shionogi Inc., a company that has been providing innovative medicines essential to people's health."

Prasco is the leading Authorized Generics company having brought more Authorized Generics to market than any other company. Prasco Authorized Generics are identical to the NDA brand product. Prasco partners with established brand companies to bring their products to the generics marketplace as Authorized Generics, which offers alternatives for consumers and pharmacists.

Mefenamic Acid Capsules are AB-rated, therapeutically equivalent and substitutable for the brand Ponstel. For additional important information, please click here to see the Full Prescribing Information, INCLUDING BOXED WARNING.

Ponstel® is a registered trademark of Shionogi Inc.

About Prasco Laboratories

Prasco is the privately held healthcare company located in Mason, Ohio, that specializes in Authorized Generics.  Prasco Authorized Generics provide patients with the identical brand drug experience at a price that competes with generics. Prasco Authorized Generics also simplify interactions between pharmacists and consumers because they are identical to branded drugs. Moreover, Prasco Authorized Generics offer brand pharmaceutical companies a strategic lifecycle management solution.

Prasco sells its product line through the major distribution channels, and operates from a cGMP compliant, VAWD certified 160,000 sq. ft. office and distribution center including DEA-approved capabilities for Schedule II-V controlled drug products and cold-chain distribution. For more information, visit www.prasco.com.  

CONTACT:  Kimberly A. Carroll
Advisor to the Chairman,
Corporate Marketing & Communications
k.carroll@prasco.com
513.204.1277
513.550.1473 C
Website:  www.prasco.com


'/>"/>
SOURCE Prasco Laboratories
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/5/2017)... 5, 2017  In response to the nationwide ... Maxillofacial Surgeons (AAOMS) released prescribing recommendations that urge ... used as a first-line therapy to manage a ... Recognizing the value and importance ... "Opioid Prescribing: Acute and Postoperative Pain Management" stresses ...
(Date:10/2/2017)... 2, 2017  Eli Lilly and Company (NYSE: ... the third quarter of 2017 on Tuesday, October 24, ... that day with the investment community and media to ... conference call will begin at 9 a.m. Eastern time. ... live webcast of the conference call through a link ...
(Date:9/28/2017)... WASHINGTON , Sept. 28, 2017 Cohen ... to advance the use of wearable and home sensors ... brain disorders. Early Signal Foundation, a nonprofit organization focused ... populations, will provide an affordable analytical system to record ... ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are ... cessation in breathing. Oral appliances can offer significant relief to about 75 percent ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one ... an innovative new design of the shoulder pad. The shoulder pad provides optimal ... controlling your pain while using cold therapy. By utilizing ice and water that is ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...
(Date:10/12/2017)... ... 12, 2017 , ... Leading pediatric oncology experts at Children’s National Health ... Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired ... Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health Literacy Innovations (HLI), creator ... tool, and the Cancer Patient Education Network (CPEN), an independent professional organization that ... new strategic alliance. , As CPEN’s strategic partner, HLI will help support ...
Breaking Medicine News(10 mins):